8-K: Theriva Biologics Cleared for Pancreatic Cancer Trial

Theriva Biologics has received regulatory approval to begin its VIRAGE2 Phase 2a clinical trial evaluating a more frequent dosing regimen of its VCN-01 therapy in combination with standard chemotherapy for metastatic pancreatic cancer.

Summary

• Theriva Biologics announced on July 7, 2026, that the Spanish Agency of Medicines and Medical Devices (AEMPS) has authorized the initiation of the VIRAGE2 clinical trial.
• This Phase IIa trial is a single-arm, single-center, open-label, proof-of-concept study evaluating an increased frequency dosing of zabilugene almadenorepvec (VCN-01) in combination with gemcitabine/nab-paclitaxel for patients with newly-diagnosed metastatic pancreatic cancer.
• The VIRAGE2 trial builds upon positive results from the VIRAGE Phase 2b trial, where patients receiving two doses of VCN-01 three months apart showed significantly improved overall survival, progression-free survival, and duration of response compared to those receiving one dose or chemotherapy alone.
• Both the EMA and FDA had previously acknowledged the improved survival with two doses of VCN-01 and suggested exploring more frequent dosing.
• The VIRAGE2 trial aims to assess the feasibility of administering at least three doses of VCN-01 every two months, in combination with standard-of-care chemotherapy.
• Results from VIRAGE2 will guide the VCN-01 dosing regimen for a potential future pivotal Phase 3 trial.
• The trial will enroll 6 evaluable patients in Spain and will assess the safety and tolerability of more frequent VCN-01 dosing, as well as VCN-01 levels in the blood.
• Secondary endpoints include objective response rate, duration of response, progression-free survival, and overall survival.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to regulatory approval for a new trial building on promising prior data, though the inherent risks of clinical development and financing needs temper the score.

Positives

• Regulatory authorization received from AEMPS to proceed with the VIRAGE2 clinical trial.
• The VIRAGE2 trial is designed to explore a potentially more effective dosing regimen for VCN-01 based on positive prior trial results.
• Previous VIRAGE trial showed significantly improved survival outcomes with two doses of VCN-01 compared to one dose or chemotherapy alone.
• EMA and FDA have recognized the potential of repeated VCN-01 dosing.
• The new trial aims to evaluate at least three doses of VCN-01 every two months, potentially leading to greater clinical benefits.
• VCN-01 has a unique mode-of-action designed to degrade tumor stroma and enhance anti-tumor immune response.
• VCN-01 has been administered to 142 patients across various cancer types in prior trials.

Negatives

• The VIRAGE2 trial is a proof-of-concept study with a small number of evaluable patients (6).
• The study is not formally powered for evaluation of clinical efficacy endpoints.
• The company's ability to raise capital and commence planned clinical trials remains subject to financing.

Risks

• The company's ability to obtain development funding and/or partnerships.
• The commencement of planned clinical trials remains subject to sufficient financing.
• The company's ability to raise capital and/or enter into strategic alternatives.
• The company's ability to reach clinical milestones when anticipated.
• Generating clinical data that establishes VCN-01 may improve patient outcomes in cancer patients.
• The ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements.
• Regulatory limitations relating to the company's ability to promote or commercialize its product candidates for specific indications.
• Acceptance of the company's product candidates in the marketplace.
• Developments by competitors that render such products obsolete or non-competitive.
• The company's ability to maintain license agreements.
• The continued maintenance and growth of the company's patent estate.
• The ability to continue to remain well financed.

Future Outlook

Results from the VIRAGE2 trial will inform the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial. More frequent repeated dosing of VCN-01 is expected to enable more potent degradation of the tumor stroma and elicit earlier induction of an antitumor immune response. If feasible, more frequent repeated dosing could significantly improve potential clinical benefits in future trials with various treatments.

Management Comments

• "We are excited to start this important exploratory clinical trial to refine the VCN-01 dosing regimen," said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
• "From the first VIRAGE trial we learned that repeated dosing of VCN-01 can lead to improved clinical outcomes in first-line metastatic PDAC patients receiving gemcitabine/nab-paclitaxel SoC chemotherapy."
• "We expect more frequent repeated dosing of VCN-01 to enable more potent degradation of the tumor stroma and elicit earlier induction of an antitumor immune response."

Industry Context

StockSavvy.ai notes that Theriva Biologics' announcement aligns with the ongoing industry trend of optimizing drug delivery and dosing regimens to maximize therapeutic efficacy, particularly in challenging indications like metastatic pancreatic cancer. The focus on combination therapies and leveraging prior trial data for future development is a common strategy in the competitive biopharmaceutical landscape.

Comparison to Industry Standards

• The VIRAGE trial, a Phase 2b study with 112 patients, is a standard size for generating preliminary efficacy data in oncology.
• The VIRAGE2 trial, a Phase 2a proof-of-concept study with 6 evaluable patients, is a common approach to explore dose optimization before committing to larger, more expensive Phase 3 trials.
• The use of gemcitabine/nab-paclitaxel as standard-of-care chemotherapy in metastatic pancreatic cancer is consistent with current treatment guidelines.
• The development of oncolytic viruses like VCN-01 is an active area of research within the biopharmaceutical industry, with several companies exploring similar modalities for various cancers.

Stakeholder Impact

• Shareholders: Potential for future value creation if VCN-01 proves successful in later-stage trials and gains regulatory approval. However, continued financing needs and clinical trial risks present uncertainty.
• Patients: Potential for improved treatment options for metastatic pancreatic cancer if the more frequent dosing regimen proves effective and safe.
• Healthcare Providers: Will be involved in the clinical trial and may adopt new treatment protocols if VCN-01 demonstrates significant benefits.

Next Steps

• Initiate the VIRAGE2 clinical trial.
• Evaluate the feasibility of administering at least 3 doses of VCN-01 given 2 months apart in combination with SoC chemotherapy.
• Inform the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial.
• Assess adverse event profile and levels of VCN-01 viral genomes in blood as primary endpoints.
• Evaluate secondary endpoints including objective response rate, duration of response, progression-free survival, and overall survival.

Key Dates

Recommendation

The announcement of regulatory approval for a new clinical trial is a positive step, building on prior encouraging data. However, the trial is early-stage (Phase 2a, proof-of-concept) and not powered for efficacy, and the company's reliance on future financing and the inherent risks of drug development warrant a cautious 'hold' recommendation until more definitive efficacy and safety data emerge from later-stage trials.

Keywords

Theriva Biologics, VCN-01, zabilugene almadenorepvec, VIRAGE2, VIRAGE, pancreatic cancer, metastatic pancreatic cancer, pancreatic ductal adenocarcinoma, PDAC, clinical trial, Phase IIa, AEMPS, EMA, FDA, oncolytic adenovirus, gemcitabine, nab-paclitaxel, chemotherapy, cancer therapeutics